title: ASPECCT: panitumumab versus cetuximab for colorectal cancer--authors' reply.
authors.affiliation: Department of Haematology-Oncology, Queen Elizabeth Hospital, Woodville, SA, 5011, Australia. Electronic address: timothy.price@health.sa.gov.au.
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Price
authors.affiliation: Antwerp University Hospital and University of Antwerp, Edegem, Belgium.
authors.forename: Marc
authors.initials: M
authors.lastname: Peeters
authors.affiliation: University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa.
authors.forename: Paul
authors.initials: P
authors.lastname: Ruff
authors.affiliation: Amgen, Thousand Oaks, CA, USA.
authors.forename: Swaminathan
authors.initials: S
authors.lastname: Murugappan
authors.affiliation: Amgen, Thousand Oaks, CA, USA.
authors.forename: Roger
authors.initials: R
authors.lastname: Sidhu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents